Colorectal cancer is one of the most common and deadliest cancers worldwide and there is an urgent need for novel therapies [46,47] It would be interesting to test the effect of the most active derivatives on colorectal cancer cell lines with mutant p53 as the majority of observed mutations in human cancers are missense-type, some of them conferring oncogenic “gain-of-function” mechanisms [28]. Here, TP53 is linked to colorectal cancer.